The Biden-Harris Administration recently announced various actions to lower healthcare and prescription drug costs. In one action, the National Institute of Standards and Technology (NIST) released in December 2023 a draft...more
2/2/2024
/ Bayh-Dole Act ,
Biden Administration ,
Comment Period ,
Disclosure Requirements ,
Drug Pricing ,
Federal Funding ,
Healthcare ,
Healthcare Reform ,
Innovation Patent ,
Inventions ,
Licensees ,
March-in-Rights ,
NIST ,
Patent Applications ,
Patent Ownership ,
Patents ,
Pharmaceutical Industry ,
Prescription Drugs ,
Public Comment
Organizations that receive federal funds or that license technology from third parties that receive Federal funds need to be aware of Federal funding obligations under the Bayh-Dole Act. Any invention conceived or reduced to...more
7/29/2020
/ Bayh-Dole Act ,
Compliance ,
Disclosure Requirements ,
Employment Contract ,
Federal Contractors ,
Federal Funding ,
Inventions ,
IP License ,
National Institute of Health (NIH) ,
Patent Applications ,
Patent Ownership ,
Patent Prosecution ,
Reporting Requirements ,
Retaining Party
Long before the AIA, declarations were a tool that was available during patent prosecution to put evidence, e.g., post-filing data and expert opinions, in front of an Examiner to rebut obviousness or lack of enablement...more
7/24/2020
/ 37 C.F.R. § 1.132 Declaration ,
Administrative Procedure ,
America Invents Act ,
Declaration ,
Defense Strategies ,
Enablement Inquiries ,
Evidence ,
Inter Partes Review (IPR) Proceeding ,
Litigation Strategies ,
Obviousness ,
Patent Prosecution ,
Patent Trial and Appeal Board ,
Post-Grant Review ,
Pre-AIA Patents ,
Standard of Proof ,
USPTO
Businesses and nonprofits that receive funding under a federal government agreement (e.g., contract, cooperative agreement, or grant) executed after May 14, 2018, are subject to the updated regulatory provisions that...more